BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  COVID-19 Brief: Omicron Mutating, Lasting Longer and Killing Faster

  As Omicron continues to dominate globally, research is coming in every day on this highly contagious variant of SARS-CoV-2.

  January 25, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Bayer-Backed Biotech Snags $80M Series A for AI-Powered Cell Therapies

  Cellino is a closed loop cell therapy manufacturing company that aims to make stem cell-based regenerative therapies available to all eligible patients and researchers using cells in clinical research.

  January 25, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Leyden Labs Aims $140 Million More at Severe Respiratory Infections

  Leyden Labs secured $140 million in a Series B financing round. Combined with $40 million from a Series A round in March 2021, the company has significant funding to advance its portfolio of candidates.

  January 25, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Money on the Move: January 19 – 25

  Temps are falling and so is investor cash. Here’s which biotech companies are scooping up the dollars this week.

  January 25, 2022

   · 

  4 min read

   · 

  Kate Goodwin
• 

  FDA

  Omicron Too Much for Lilly, Regeneron Treatments as FDA Curbs Use

  The FDA cited data demonstrating that both treatments are not likely to be potent against omicron and should not be authorized for use in any U.S. state, territory, and jurisdiction for the time being.

  January 25, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Myelofibrosis Drug Meets Primary and Key Secondary Endpoints in Phase 3

  The Phase III MOMENTUM trial showed that momelotinib was able to meet its primary endpoint by week 24, specifically a TSS reduction of over 50% compared to the baseline figures.

  January 25, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  BlueWillow’s Non-Viral Intranasal Vaccine Enhances Immunity and Broadens Options

  In addition to the induction of both mucosal and systemic immunity, advantages of an intranasal approach include the lack of needles, low cost and thermostability under normal refrigeration temperature.

  January 25, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Biotech Bay

  Metagenomi’s Gene Editing Programs Take $175 Million Leap Forward

  Metagenomi announced the completion of an oversubscribed $175 million Series B financing round, bringing the company’s total funding to $300 million.

  January 25, 2022

   · 

  2 min read

   · 

  Jill Gartz
• 

  Drug Development

  89bio Proof of Concept Study Sparks Glimmer of Excitement in NASH

  Sixty-three percent of patients met the primary endpoint of a 2-point or greater improvement in disease severity without worsening of fibrosis.

  January 25, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  FDA Pulls on the Reins for Mustang’s Gene Therapy as Others Advance

  Shares of Mustang Bio have fallen more than 13% in premarket trading after announcing the FDA had placed a hold on the company’s Investigational New Drug application for its bubble boy gene therapy.

  January 25, 2022

   · 

  4 min read

   · 

  Alex Keown